Search Videos and More

Showing 1 - 12 of 120 results

Previous| 1 | 2 | 3 ...10 |Next


Dana-Farber Research Publication 5.15.2022 News

Dana-Farber Research Publication 5.15.2022

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
Newly Identified Regulator in Prostate Cancer Cells Could Serve as Drug Target for Advanced Tumors News

Newly Identified Regulator in Prostate Cancer Cells Could Serve as Drug Target for Advanced Tumors

Aiming to discover new targets for blocking androgen receptor activity, a Dana-Farber-led team has identified a critical regulator of AR signaling that prostate cancer cells depend on, according to their publication in Cell Reports.
Treatment Guidelines: Adjuvant Abemaciclib for Early-Stage, Hormone-Receptor-Positive Breast Cancer Document

Treatment Guidelines: Adjuvant Abemaciclib for Early-Stage, Hormone-Receptor-Positive Breast Cancer

Dana-Farber Brigham Cancer Center Breast Oncology Center (BOC) held multidisciplinary meetings on October 15 and November 5, 2021, to discuss recommendations for the use of abemaciclib in patients with early-stage, high-risk, HR+ breast cancer.
Treatment Guidelines: Pembrolizumab for Early-Stage Triple-Negative Breast Cancer Document

Treatment Guidelines: Pembrolizumab for Early-Stage Triple-Negative Breast Cancer

Dana-Farber Brigham Cancer Center Breast Oncology Center (BOC) held multidisciplinary meetings on August 4, September 3, and October 8, 2021 to discuss recommendations for the use of pembrolizumab in patients with early-stage TNBC.
Breast Cancer Treatment Guidelines Symposium

Breast Cancer Treatment Guidelines

Following the FDA approval of certain treatments for breast cancer, the faculty in the Breast Oncology Program at Dana-Farber Brigham Cancer Center met to formalize guidelines for how to best utilize the new medications.
Dana-Farber Research Publications News

Dana-Farber Research Publications

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
2022 Society of Gynecologic Oncology (SGO) Symposium

2022 Society of Gynecologic Oncology (SGO)

DFCI Faculty share highlights from the Society of Gynecologic Oncology Annual Meeting on Women's Cancers held on March 18-21, 2022, in Phoenix, AZ and online.
Dana-Farber Cancer Institute Celebrates 75th Anniversary News

Dana-Farber Cancer Institute Celebrates 75th Anniversary

Dana-Farber Cancer Institute launched a year-long celebration of its 75th anniversary to highlight its history and progress in cancer care and transformative cancer research. In marking the notable anniversary, Dana-Farber seeks to recognize the Institute’s many scientific discoveries, advancements in cancer care for patients, and its extraordinary contributions to eradicating cancer in both children and adults.
Lymphoma and Chronic Lymphocytic Leukemia: Updates in Management News

Lymphoma and Chronic Lymphocytic Leukemia: Updates in Management

This course will address the rapidly changing landscape in the management and treatment of non-Hodgkin lymphoma, Hodgkin Lymphoma, and chronic lymphocytic leukemia
Conjugate Therapy Produces Remissions in One-Third of Patients with Drug-Resistant Ovarian Cancer, Study Results Show News

Conjugate Therapy Produces Remissions in One-Third of Patients with Drug-Resistant Ovarian Cancer, Study Results Show

In a clinical trial involving patients with ovarian cancer previously treated with platinum-based chemotherapy, a novel “conjugate” therapy produced a substantially better response than standard treatments. Results from this study were presented by Dana-Farber's Ursula Matulonis, MD during a plenary session at the SGO 2022 Annual Meeting.
Drug Combination Shows Effectiveness in Patients with Recurrent ER-Positive Endometrial Cancer News

Drug Combination Shows Effectiveness in Patients with Recurrent ER-Positive Endometrial Cancer

A combination therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in 75% of patients with recurrent or persistent estrogen receptor- (ER-) positive endometrial cancer. Results from this trial were shared by Panos Konstantinopolous, MD, PhD during a plenary session at the SGO 2022 Annual Meeting.
ASCO GU Symposium Highlights Symposium

ASCO GU Symposium Highlights

In the following videos, faculty from Dana-Farber Cancer Institute review highlights from the 2022 ASCO GU Symposium

Showing 1 - 12 of 120 results

Previous| 1 | 2 | 3 ...10 |Next